摘要
目的观察Ⅲ期非小细胞肺癌同步放化疗前后血清CEA、CA125、CYFRA21-1的表达情况。方法采用电化学发光免疫学测定方法检测40例Ⅲ期非小细胞肺癌患者同步放化疗前后外周血清中CEA、CA125、CYFRA21-1的表达水平。结果同步放化疗前腺癌组外周血清中CEA表达明显高于鳞癌组;鳞癌组外周血清中CA125和CYFRA21-1表达高于腺癌组,同步放化疗后CEA、CA125、CYFRA21-1的表达较前下降,差异均有统计学意义(P<0.05)。结论Ⅲ期非小细胞肺癌同步放化疗前后血清中CEA、CA125、CYFRA21-1的表达水平可作为其疗效判定的指标。
Objective To study the clinical significance of changes of serum CEA, CA12-5 and C YFRA21-1 levels before and after concurrent chemoradiation in m period non-small cell lung cancer. Methods The expression of changes of serum CEA, CA12-5 and CYFRA21-1 levels before and after concurrent chemoradiation in m period non-small cell lung cancer were detected by electrechem- iluminesccnce immunoassay. Results Before treatment, serum CEA levels in adenocareinoma were higher than thode in squamous cell carcinoma, but serum CA12-5, CYFRA21-1 levels in squamous cell carcinoma was higher than those adenocareinoma. After treatment, serum CEA, CA12-5 and CYFRA21-1 levels decreased more greatly with significant differences compared with before treatment （ P 〈 0. 05 ）. Conclusion Serum CEA, CA12-5 and C YFRA21-1 levels before and after concurrent chemoradiation in m period non-small cell lung cancer can be a therapeutic efficacy index.
出处
《临床肺科杂志》
2012年第10期1852-1854,共3页
Journal of Clinical Pulmonary Medicine
关键词
非小细胞肺癌
肿瘤标记物
同步放化疗
non-small-cell lung carcinoma
tumor markers
concurrent chemoradiation
